Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12durvalumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × amivantamab × Clear all
NCT02609776 2026-06-05

CHRYSALIS

Janssen Research & Development, LLC

Phase 1 Active not recruiting
751 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
1,074 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

Janssen Research & Development, LLC

Phase 3 Active not recruiting
308 enrolled 12 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Janssen Research & Development, LLC

Phase 3 Active not recruiting
776 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡